Cancer immunotherapy

Applied DNA Biotherapeutics Subsidiary LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development

Retrieved on: 
Monday, July 25, 2022
Other Health, Research, General Health, Pharmaceutical, Biometrics, Genetics, Clinical Trials, Science, Veterinary, Biotechnology, Other Science, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DNA, Vaccine, BioRxiv, Infection, Severe acute respiratory syndrome coronavirus 2, DNA vaccine, Zoonosis, Twitter, Applied DNA Sciences, Food, Polymerase chain reaction, CEO, Forward-looking statement, SEC, History, Research, Securities Act of 1933, Securities Exchange Act of 1934, Private Securities Litigation Reform Act, Safety, COVID-19, PETS, RNA transfection, NASDAQ, United States Department of State, Preprint, Cat, Leadership, Clinical trial, Biotechnology, USDA, Technology, FDA, LinkedIn, Therapy, Annual report, Drug Quality and Security Act, LNP, United States Department of Agriculture, Lymphoma, Cancer immunotherapy, PCR, Manuscript, Veterinary medicine

The manuscript, authored by LineaRx, the Companys majority-owned biotherapeutics subsidiary, and LineaRxs development partner, EvviVax, S.R.L., further establishes the utility of the LinearDNA ("linDNA) platform as a large-scale enzymatic production approach to prophylactic and therapeutic veterinary vaccine applications.

Key Points: 
  • The manuscript, authored by LineaRx, the Companys majority-owned biotherapeutics subsidiary, and LineaRxs development partner, EvviVax, S.R.L., further establishes the utility of the LinearDNA ("linDNA) platform as a large-scale enzymatic production approach to prophylactic and therapeutic veterinary vaccine applications.
  • It details positive data showing safety and immunogenicity of a linDNA vaccine candidate against SARS-CoV-2 in a cohort of family-owned cats.
  • Separately, LineaRx announced the successful expression in vitro of its linDNA SARS-CoV-2 vaccine candidate encapsulated within lipid nanoparticles (LNP).
  • Evvivax pursues the discovery and development of innovative Therapeutic Veterinary Cancer Vaccines based on proprietary viral vectors and DNA platform technologies.

Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™  Dietary Supplementation

Retrieved on: 
Friday, July 22, 2022
Ivermectin, Legislation, Apoptosis, Company, Method, PCR, Infection, Severe acute respiratory syndrome coronavirus 2, Brain, Knowledge, Cancer immunotherapy, U.S. Securities and Exchange Commission, Research, Solution, Cell cycle, TBIA, Biotechnology, Technology, Synthase, ResearchGate, IC50, Virus, Monocyte, GLOBE, PASC, MERS, Immune system, COVID-19, Preprint, Protease inhibitor (pharmacology), Cancer, OTCQB, Pressure, Plasma, Neuron, Lymphocyte, Alzheimer's disease, RN, Neurodegeneration, Patient, TMB-2, Pharmaceutical industry, Medical imaging, Pharma, COVID, Long COVID

COVID-19 and Acute Sequelae of SARS-CoV-2 (PASC), or Long COVID, are major public health problems.

Key Points: 
  • COVID-19 and Acute Sequelae of SARS-CoV-2 (PASC), or Long COVID, are major public health problems.
  • We report a case of a patient with SARS-CoV-2 infection and persistent Long COVID symptoms for over 2 years, who received the therapeutic intervention Paxlovid.
  • After finding no relief using Paxlovid, the subject initiated supplementation with the 3CL protease inhibitor immune support dietary supplement Tollovid.
  • Preliminary data from an ongoing IRB-waiver study of customers who used the products to assist with their COVID and Long COVID was recently announced.

Todos Medical Reports Case Study #7 in Acute and Long COVID

Retrieved on: 
Tuesday, July 12, 2022
Technology, Biotechnology, Pathology, TMB-2, United, Patient, Cancer immunotherapy, Synthase, PASC, Chills, JNJ, Vitamin D deficiency, U.S. Securities and Exchange Commission, Knowledge, Method, Lymphocyte, Apoptosis, Boxing, Company, Alzheimer's disease, Brain, GLOBE, Vitamin D, RN, Virus, Cell cycle, Neurodegeneration, Solution, Neuron, COVID-19, Legislation, Plasma, Pressure, IC50, Fatigue, Female, OTCQB, Ivermectin, MERS, Severe acute respiratory syndrome coronavirus 2, TBIA, Cancer, Yoga, Monocyte, Research, Immune system, PCR, Fever, Pharmaceutical industry, Animal, Vaccine, Medical imaging, Pharma, COVID

This case study suggests there was underlying COVID-19 disease pathology not detected by traditional antigen and PCR tests.

Key Points: 
  • This case study suggests there was underlying COVID-19 disease pathology not detected by traditional antigen and PCR tests.
  • In March 2022, Long COVID symptoms developed as her immune system was actively trying to rid the body of pathogen.
  • Preliminary data from an ongoing IRB-waiver study of customers who used the products to assist with their COVID and Long COVID was recently announced.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients

Retrieved on: 
Thursday, June 30, 2022
MERS, Patient, Research, Neurodegeneration, Legislation, GLOBE, COVID-19, Company, CRP, Immune system, Shaare Zedek Medical Center, D-dimer, EUA, Cancer immunotherapy, Severe acute respiratory syndrome coronavirus 2, Cell cycle, Knowledge, Apoptosis, TMB-2, OTCQB, Pressure, Monocyte, Neuron, Solution, Alzheimer's disease, Emergency Use Authorization, CEO, Biotechnology, COVID, Brain, TBIA, IC50, Inflammation, Technology, IL-6, Virus, PCR, US Foods, Ivermectin, Method, Review, Biomarker, U.S. Securities and Exchange Commission, Plasma, Lymphocyte, Synthase, Literature, Cancer, Pharmaceutical industry, Medical imaging, Delta, Pharma

New York, NY, and Tel Aviv, ISRAEL, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced biomarker data from its majority-owned joint venture 3CL Pharma Ltd.’s Phase 2 clinical trial of Tollovir™ in hospitalized COVID-19 patients. The data showed a positive correlation between the clinical data announced for Tollovir on January 27, 2022 and biomarkers associated with acute phase immune response (IL-6), inflammation (C reactive protein), blood clotting (D-dimer) and immune response to COVID-19 (cPass neutralizing antibodies). Additionally, renal and hepatic biomarker data showed no signals of treatment-associated risk with Tollovir therapy.

Key Points: 
  • Additionally, renal and hepatic biomarker data showed no signals of treatment-associated risk with Tollovir therapy.
  • Recent peer reviewed literature shows the predictability of key biomarker data such as IL-6, CRP, and D-Dimer in the hospitalized setting.
  • We believe the correlative biomarker data, in addition to the positive clinical results previously reported in hospitalized patients primarily from the Delta variant wave,should elevate Tollovirs profile in the eyes of regulators, said Gerald Commissiong, President & CEO of Todos Medical and Interim-CEO of 3CL Pharma.
  • Tollovir has successfully completed a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19.

Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID

Retrieved on: 
Thursday, June 23, 2022
Cancer, Cancer immunotherapy, MERS, COVID-19, Neuron, IC50, Apoptosis, Technology, Method, CEO, TMB-2, Company, Knowledge, Brain, Capsule, Synthase, U.S. Securities and Exchange Commission, Biotechnology, Trial of the century, Virus, Research, Pressure, TBIA, Cell cycle, OTCQB, Disease, Monocyte, Severe acute respiratory syndrome coronavirus 2, Immune system, Interim, Ivermectin, Plasma, Alzheimer's disease, Neurodegeneration, Legislation, Patient, Lymphocyte, COVID, PCR, Pharmaceutical industry, Medical imaging, Pharma

NEW YORK, NY, and TEL AVIV, ISRAEL, June 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced preliminary data from its majority-owned joint venture 3CL Pharma Ltd.’s ongoing IRB-waived sponsored market research study of the commercial use of Tollovid® as a dietary supplement. Among the first 41 respondents, of whom 78% were fully vaccinated against COVID-19, 13 reported that they began to use Tollovid when they were diagnosed with active COVID infection, whereas 28 respondents reported that they used Tollovid to address their Long COVID symptoms. 15 of the Long COVID respondents had experienced symptoms for up to 9 months (‘Short’ Long COVID), and 12 of the Long COVID respondents reported having symptoms for over 9 months (‘Chronic’ Long COVID). 18 of the 24 respondents who answered the question “Who diagnosed your Long COVID?” indicated that they were diagnosed by a medical professional. The preliminary results of the market research study are marked in the table below:

Key Points: 
  • Respondents to the market research survey generally followed the directions on the Tollovid label, taking 12 capsules per day for 5 days among Acute COVID respondents, and taking at least 2 bottles of Tollovid according to the directions among Long COVID respondents.
  • This market research study is not designed to assess optimal Tollovid dosing.
  • Tollovid Dailys 3CL protease IC50 binding affinity is at least two and a half times (2.5x) as Ivermectin.
  • Tollovid and Tollovid Daily bind to the active site (receptor binding domain) of the 3CL protease.

Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff

Retrieved on: 
Tuesday, June 21, 2022
MERS, Pressure, OTCQB, Plasma, Legislation, U.S. Securities and Exchange Commission, PCR, GLOBE, Solution, Cancer, Cancer immunotherapy, Therapy, Amazon, Neuron, Technology, CEO, Brain, Synthase, Biotechnology, Monocyte, Immune system, Phase, Lymphocyte, LTD, Freedom, COVID-19, IC50, Apoptosis, Knowledge, Alzheimer's disease, Patient, COVID, Disability, Method, TMB-2, Company, Research, TBIA, Cell cycle, Severe acute respiratory syndrome coronavirus 2, Ivermectin, Long COVID, Neurodegeneration, Pharmaceutical industry, Medical imaging, Pharma

The Moneta team is very well positioned to help Todos get to the next level, said Gerald Commissiong, President & CEO at Todos Medical.

Key Points: 
  • The Moneta team is very well positioned to help Todos get to the next level, said Gerald Commissiong, President & CEO at Todos Medical.
  • Tollovid's 3CL protease IC50 binding affinity is at least ten times (10x) as strong as Ivermectins published 3CL protease IC50 binding affinity.
  • Tollovid Dailys 3CL protease IC50 binding affinity is at least two and a half times (2.5x) as Ivermectin.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA™ Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research

Retrieved on: 
Monday, June 6, 2022
Research, Other Health, Oncology, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Science, Veterinary, Biotechnology, FDA, Health, Other Science, USDA, Company, Paper, Survival, BioRxiv, PETS, CRISPR, Cannabis, COVID-19 testing, PCR, COVID-19, History, Cancer, TCR, Infection, Association, Textile, Journal, Food, Forward-looking statement, CEO, TERT, United States Department of Agriculture, Trial of the century, Securities Exchange Act of 1934, Dog, Securities Act of 1933, Russell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Calendar, Cancer immunotherapy, Vaccine, Annual report, RNA, Lymphoma, Journal of Experimental & Clinical Cancer Research, DNA, SEC, Private Securities Litigation Reform Act, Experiment, Program, Research, LNP, Drug Quality and Security Act, LinkedIn, FDA, EGT, NASDAQ, Twitter, Clinical trial, United States Department of State, Zoonosis, Pharmaceutical industry, Applied DNA Sciences, Veterinary medicine

("EvviVax"), today announced the peer-reviewed publication of preclinical animal data in The Journal of Experimental & Clinical Cancer Research that supports the use of Applied DNAs LinearDNA platform to produce veterinary DNA cancer vaccines.

Key Points: 
  • ("EvviVax"), today announced the peer-reviewed publication of preclinical animal data in The Journal of Experimental & Clinical Cancer Research that supports the use of Applied DNAs LinearDNA platform to produce veterinary DNA cancer vaccines.
  • LinearDNA is Applied DNA's proprietary, large-scale polymerase chain reaction (PCR)-based manufacturing platform that allows for the large-scale, cell-free production of high-fidelity DNA sequences.
  • Applied DNA has exclusively licensed the anti-telomerase reverse transcriptase (TERT) cancer vaccine studied in the paper for its LinearDNA platform for veterinary applications.
  • The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market.

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

Retrieved on: 
Monday, June 6, 2022
Research, Venture Capital, Professional Services, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Cancer immunotherapy, Beacon, Cell, R, FOR, Antibody, GMP, Nasdaq, Solution, Multimedia, Therapy, U.S. Securities and Exchange Commission, CDMO, Workflow, Risk, RESEARCH, Adoption, AMRI, Light, Drug discovery, Fine chemical

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curias adoption of The Beacon Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.

Key Points: 
  • Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curias adoption of The Beacon Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.
  • The Pentamice platform, CHO-GSN and TunaCHO platforms were developed at LakePharma, which Curia acquired in 2021.
  • Advanced technologies such as the Berkeley Lights platform are revolutionizing antibody discovery, tackling key pain points that confront innovators, such as long timelines and limited number of sequences.
  • We are excited to partner with Curia, a leading CDMO, in their adoption of the Berkeley Lights platform for antibody discovery.

Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference

Retrieved on: 
Friday, May 27, 2022
Knowledge, U.S. Securities and Exchange Commission, Mortality, Legislation, Plasma, Conference, Data, Monocyte, Immune system, OTCQB, National Early Music Association, Clinical trial, COVID-19, Method, Research, Brain, Alzheimer's disease, Pressure, Cell cycle, GLOBE, Company, IC50, Solution, Coronavirus, Neurodegeneration, Pharma, Biotechnology, Synthase, PCR, Apoptosis, COVID, Cancer, Severe acute respiratory syndrome coronavirus 2, Pacific Time Zone, Cancer immunotherapy, TMB-2, Patient, Ivermectin, Lymphocyte, Neuron, Personalized medicine, Technology, MERS, TBIA, CEO, Pharmaceutical industry, Medical imaging

Tollovid's 3CL protease IC50 binding affinity is at least ten times (10x) as strong as Ivermectins published 3CL protease IC50 binding affinity.

Key Points: 
  • Tollovid's 3CL protease IC50 binding affinity is at least ten times (10x) as strong as Ivermectins published 3CL protease IC50 binding affinity.
  • Tollovid Dailys 3CL protease IC50 binding affinity is at least two and a half times (2.5x) as Ivermectin.
  • Tollovir has successfully completed a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19.
  • Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19.

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim

Retrieved on: 
Monday, May 2, 2022
COVID-19, Cancer immunotherapy, Immune system, Brain, U.S. Securities and Exchange Commission, MERS, Maintenance, TMB-2, GLOBE, Monocyte, Company, Ivermectin, Biotechnology, Plasma, CFS, Alzheimer's disease, Legislation, PCR, Cell cycle, Patient, COVID, Neuron, Coronavirus, Lymphocyte, Apoptosis, NSP5, Amazon, Knowledge, Pressure, OTCQB, US Foods, TBIA, Severe acute respiratory syndrome coronavirus 2, Method, Sale, Disease, Language, Solution, Technology, Research, Synthase, Cancer, Neurodegeneration, IC50, Pharmaceutical industry, Dietary supplement, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, May 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. has received a new certificate of free sale (CFS) from the US Food & Drug Administration whose label provides for both a 5-day support dosing regimen and a 30-day maintenance dosing regimen of Tollovid® Maximum Strength and reiterates the 3CL protease (3CLpro, Mpro, NSP5) in vitro inhibitor language allowed on prior labels for Tollovid®. The Company believes this new CFS will help customers more easily navigate using the product given the recent increase in interest for Tollovid®.

Key Points: 
  • Tollovid is not approved to diagnose, treat, prevent or cure any disease, including COVID or Long COVID (also known as Post-Acute Sequalae of SARS-CoV-2, or PASC)).
  • Tollovid's 3CL protease IC50 binding affinity is at least ten times (10x) as strong as Ivermectins published 3CL protease IC50 binding affinity.
  • Tollovid Dailys 3CL protease IC50 binding affinity is at least two and a half times (2.5x) as Ivermectin.
  • Tollovid and Tollovid Daily bind to the active site (receptor binding domain) of the 3CL protease.